Stock PSYB.H PSYBIO THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases PsyBio Therapeutics Corp.

Equities

PSYB.H

CA6936971044

Delayed Toronto S.E.
Other stock markets
 04:24:13 29/03/2024 GMT 		5-day change 1st Jan Change
0.01 CAD -.--% Intraday chart for PsyBio Therapeutics Corp. -.--% -.--%
2021 PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs CI
2021 PsyBio Therapeutics : Files Novel Psychedelic Compositions and Methods of Treatment Patent With USPTO MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PsyBio Therapeutics : Reports Second Quarter 2021 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones
AQ
PsyBio Therapeutics : Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs
AQ
PsyBio Therapeutics : Adds NMDA Receptor Antagonists and Associated Analogues into its Intellectual Property Portfolio
AQ
PsyBio Therapeutics : CEO and CMO to Participate in Fireside Chat at LifeSci Partners Summer Symposium
AQ
PsyBio Therapeutics : Announces Uplisting to OTCQB Venture Market
AQ
PsyBio Therapeutics : Augments Intellectual Property Portfolio with Filing of Next Novel Psychedelic Compositions and Methods of Treatment Patent
AQ
PsyBio Therapeutics : Announces TSXV Approval of Share Buyback Program
AQ
PsyBio Therapeutics : Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose Industrie
AQ
PsyBio Therapeutics : Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors
AQ
PsyBio Therapeutics : Retains KCSA Strategic Communications for Investor Relations Services
AQ
PsyBio Therapeutics : Strengthens its Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer
AQ
PsyBio Therapeutics Announces Retention of Market Maker
GL
PSYO THER : PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Global Contract Research, Development and Manufacturing Organization
AQ
PsyBio Announces Second Quarter Financial Results of Leo Acquisition Corp.
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PSYB.H Stock
  4. News PsyBio Therapeutics Corp.
  5. Press Releases